Abstract
Thalidomide is effective in the treatment of multiple myeloma. The immunomodulatory drug and thalidomide analogue lenalidomide is currently in late stage clinical development for MDS and multiple myeloma. This minireview highlights the course of initial and ongoing lenalidomide clinical development in oncology with reference to earlier thalidomide studies.
MeSH terms
-
Clinical Trials as Topic
-
Humans
-
Immunologic Factors
-
Immunosuppressive Agents / therapeutic use*
-
Lenalidomide
-
Multiple Myeloma / drug therapy*
-
Myelodysplastic Syndromes / drug therapy*
-
Myelodysplastic Syndromes / immunology
-
Thalidomide / analogs & derivatives*
-
Thalidomide / therapeutic use
Substances
-
Immunologic Factors
-
Immunosuppressive Agents
-
Thalidomide
-
Lenalidomide